Immix Biopharma Amends ATM Program, Increasing Potential Offering to $100 Million
IMMX has more than doubled off its 52-week low of $1.34.
Summary
Immix Biopharma, Inc. has amended its At-The-Market (ATM) offering agreement, raising the maximum aggregate offering price to $100 million, significantly increasing potential future dilution.
Key Events · Financing and Capital Events · IMMX
-
ATM Program Amended
Immix Biopharma, Inc. entered into Amendment No. 1 to its At-The-Market Offering Agreement with Citizens JMP Securities, LLC, originally dated June 3, 2025.
-
Offering Capacity Increased
The maximum aggregate offering price under the ATM program has been increased to $100,000,000, providing the company with greater capital raising potential.
-
Prospectus Supplement Filed
A prospectus supplement relating to this expanded offering was filed concurrently on March 25, 2026, under the existing S-3 registration statement (File No. 333-292665).
Analysis · IMMX · Life Sciences
This 8-K filing details an amendment to Immix Biopharma's existing At-The-Market (ATM) offering agreement, originally established on June 3, 2025. The key change is the increase in the potential aggregate offering price to $100,000,000. This substantial increase in the ATM program's capacity, representing a significant portion of the company's current market capitalization, signals a considerable potential for future dilution as the company may sell shares into the market from time to time. The concurrent filing of a prospectus supplement finalizes the terms for this expanded program, providing the company with enhanced flexibility for capital raises.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMMX was trading at $9.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $471.8M. The 52-week trading range was $1.34 to $11.61. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.